The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).
James Chih-Hsin Yang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; Genentech; InnoPharma ; Lilly; Merck Serono; Novartis; Pfizer; Roche; Takeda
Honoraria - Abbott Laboratories; AstraZeneca; Bayer; Boehringer Ingelheim; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Lecia V. Sequist
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U)
Research Funding - Boehringer Ingelheim
Martin H. Schuler
Research Funding - Boehringer Ingelheim
Tony Mok
Employment or Leadership Position - The Chinese University of Hong Kong
Consultant or Advisory Role - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Honoraria - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca
Nobuyuki Yamamoto
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly
Kenneth John O'Byrne
Consultant or Advisory Role - Boehringer Ingelheim; Lilly
Honoraria - Boehringer Ingelheim; Lilly
Research Funding - Lilly
Vera Hirsh
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Sarayut Lucien Geater
No relevant relationships to disclose
Caicun Zhou
Consultant or Advisory Role - Boehringer Ingelheim; Clovis; Lilly; Roche
Dan Massey
Employment or Leadership Position - Boehringer Ingelheim
Victoria Zazulina
Employment or Leadership Position - Boehringer Ingelheim
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Roche; Sanofi